Thomas Lynch takes board seat at Infinity Pharmaceuticals

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

Adelene Perkins moves to president of Infinity Pharmaceuticals [October 29, 2008]

Infinity’s anti-cancer drug moves into Phase 1 trials [July 30, 2008]

Infinity alliance with Purdue, Mundipharma reels in $75 million [November 21, 2008]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Infinity Pharmaceuticals Inc., a cancer drug discovery and development company in Cambridge, has named Thomas Lynch, director of the Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital, to its board of directors.

Lynch has concentrated his research on lung cancer and, most recently, to mutations of the epidermal growth factor receptor in lung cancer.

Earlier career roles for Lynch include a position as chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.

Lynch earned his M.D. from Yale University and served as a fellow in medical oncology at the Dana-Farber Cancer Institute.

Infinity (Nasdaq:INFI) was founded in 2001. In September 2006, the company completed its acquisition of Discovery Partners International Inc., a publicly traded company based in San Diego. Following that deal, reportedly worth about $100 million, Infinity became publicly traded.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.